Urticaria News and Research

RSS
Urticaria are itchy, raised red areas on the skin. Urticaria are caused by a reaction to certain foods, drugs, infections, or emotional stress. Also called hives.
FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

rEVO Biologics announces results from Atryn phase 3 studies on pregnant AT-deficient women

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG seeks FDA sNDA approval for Feraheme Injection

FDA approves GSK’s raxibacumab to treat inhalational anthrax

FDA approves GSK’s raxibacumab to treat inhalational anthrax

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Allergy Centre of the Charité-Universitätsmedizin Berlin to host three international scientific conferences

Allergy Centre of the Charité-Universitätsmedizin Berlin to host three international scientific conferences

General guidelines to understand allergic skin conditions

General guidelines to understand allergic skin conditions

Leading allergy organizations release report that sheds light on angioedema

Leading allergy organizations release report that sheds light on angioedema

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AstraZeneca commences FASLODEX Phase III study for hormone receptor-positive metastatic breast cancer

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

FDA approves Baxter's GAMMAGARD LIQUID for multifocal motor neuropathy

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

Psoriasis link with autoimmune diseases underscored

Psoriasis link with autoimmune diseases underscored

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Chinese sFDA approves Baxter's ADVATE to treat hemophilia A

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

EMA CHMP recommends approval of AMAG’s ferumoxytol

EMA CHMP recommends approval of AMAG’s ferumoxytol